Patents by Inventor William A. Gaarde

William A. Gaarde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of focal adhesion kinase expression
    Publication number: 20040192628
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Application
    Filed: August 22, 2003
    Publication date: September 30, 2004
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Publication number: 20040171566
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: August 15, 2003
    Publication date: September 2, 2004
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay, Wai Shiu Fred Wong
  • Modulation of checkpoint kinase 1 expression
    Publication number: 20040097446
    Abstract: Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.
    Type: Application
    Filed: November 16, 2002
    Publication date: May 20, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Susan M. Freier, Kenneth W. Dobie, Andrew T. Watt
  • Antisense modulation of PPAR-delta expression
    Publication number: 20040063129
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPAR-delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPAR-delta. Methods of using these compounds for modulation of PPAR-delta expression and for treatment of diseases associated with expression of PPAR-delta are provided.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 1, 2004
    Inventors: William Gaarde, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of mekk3 expression
    Publication number: 20040033976
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK3. Methods of using these compounds for modulation of MEKK3 expression and for treatment of diseases associated with expression of MEKK3 are provided.
    Type: Application
    Filed: June 13, 2003
    Publication date: February 19, 2004
    Inventors: Donna T. Ward, William A. Gaarde, Brett P. Monia, Jacqueline R. Wyatt
  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Publication number: 20040029823
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: January 15, 2003
    Publication date: February 12, 2004
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
  • Antisense modulation of EDG8 expression
    Publication number: 20040014050
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EDG8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG8. Methods of using these compounds for modulation of EDG8 expression and for treatment of diseases associated with expression of EDG8 are provided.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Kenneth W. Dobie
  • Antisense modulation of PPAR-delta expression
    Publication number: 20030224514
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPAR-delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPAR-delta. Methods of using these compounds for modulation of PPAR-delta expression and for treatment of diseases associated with expression of PPAR-delta are provided.
    Type: Application
    Filed: May 31, 2002
    Publication date: December 4, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of mekk2 expression
    Publication number: 20030212018
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.
    Type: Application
    Filed: October 25, 2002
    Publication date: November 13, 2003
    Inventors: Brett P. Monia, William A. Gaarde, Donna T. Ward, Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Publication number: 20030176383
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: September 9, 2002
    Publication date: September 18, 2003
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Antisense modulation of MEKK4 expression
    Publication number: 20030144242
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: July 31, 2003
    Inventors: Donna T. Ward, William Gaarde, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of connective tissue growth factor expression
    Publication number: 20030144223
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
    Type: Application
    Filed: December 10, 2001
    Publication date: July 31, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Andrew T. Watt
  • Antisense modulation of human collapsin response mediator protein 2 expression
    Publication number: 20030125274
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of human collapsin response mediator protein 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human collapsin response mediator protein 2. Methods of using these compounds for modulation of human collapsin response mediator protein 2 expression and for treatment of diseases associated with expression of human collapsin response mediator protein 2 are provided.
    Type: Application
    Filed: November 8, 2001
    Publication date: July 3, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Andrew T. Watt
  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Publication number: 20030004120
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: January 31, 2001
    Publication date: January 2, 2003
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela Nero, William A. Gaarde
  • Antisense modulation of TERT expression
    Patent number: 6492171
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: December 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Susan M. Freier, Edward Wancewicz
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Patent number: 6448079
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Antisense modulation of TERT expression
    Publication number: 20020045588
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Application
    Filed: December 7, 2000
    Publication date: April 18, 2002
    Inventors: Brett P. Monia, William A. Gaarde, Susan M. Freier, Edward Wancewicz
  • Antisense inhibition of tert expression
    Patent number: 6331399
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TERT. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TERT. Methods of using these compounds for modulation of TERT expression and for treatment of diseases associated with expression of TERT are provided.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: December 18, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Edward Wancewicz
  • Antisense modulation of focal adhesion kinase expression
    Publication number: 20010034329
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Application
    Filed: January 9, 2001
    Publication date: October 25, 2001
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero
  • Antisense inhibition of MEKK2 expression
    Patent number: 6287860
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Susan M. Freier, Jacqueline Wyatt